Search - tctmd.com

Displaying 521 - 540 of 551

Sort: Relevancy | Date

News Industry News

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

August 26, 2012

News Daily News

Indirect Comparisons Show Little Difference Among New Anticoagulants

August 14, 2012

News Daily News

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

August 14, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

L.A. McKeown

August 09, 2012

News Daily News

Left Atrial Appendage Morphology May Help Predict Stroke Risk in A-fib Patients

July 31, 2012

News Daily News

La Morfología del Apéndice Auricular Izquierdo Podría Ayudar a Predecir el Riesgo de ACV en Pacientes con FA

July 31, 2012

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Daily News

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

May 04, 2012

News Daily News

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

May 04, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

New Oral Anticoagulants for Stroke Prevention

Presenter: Nicole R. Gonzales

May 02, 2012

News Daily News

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

L.A. McKeown

April 30, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

Advertisement

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

Indirect Comparisons Show Little Difference Among New Anticoagulants

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

Left Atrial Appendage Morphology May Help Predict Stroke Risk in A-fib Patients

La Morfología del Apéndice Auricular Izquierdo Podría Ayudar a Predecir el Riesgo de ACV en Pacientes con FA

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

New Oral Anticoagulants for Stroke Prevention

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content